文献速递糖尿病

他汀类药物治疗降低糖尿病合并外周动脉疾病患者未来下肢截肢风险

Statin Therapy Reduces Future Risk of Lower-Limb Amputation in Patients With Diabetes and Peripheral Artery Disease.
PubMed 文献 · J Clin Endocrinol Metab · 2017-01-01

该观察性队列研究基于台湾2000至2011年全国糖尿病数据库,纳入69,332例年龄≥20岁的糖尿病合并外周动脉疾病患者,比较他汀使用者、非他汀降脂药使用者与未使用者。他汀使用者较未使用者下肢截肢风险更低(校正风险比0.75,95%置信区间0.62至0.90),院内心血管死亡和全因死亡风险也更低。

要点

  • 他汀使用者较未使用者下肢截肢校正风险比0.75(95%CI 0.62至0.90)。
  • 他汀使用者较未使用者院内心血管死亡校正风险比0.78(95%CI 0.69至0.87)。
  • 他汀使用者较未使用者全因死亡校正风险比0.73(95%CI 0.69至0.77)。

核心结论

  • 与从未接受降脂药物治疗的他汀未使用者相比,他汀使用者在糖尿病合并外周动脉疾病患者中下肢截肢和心血管死亡风险更低。

研究设计与样本

  • 观察性队列研究,数据来自台湾2000至2011年全国糖尿病数据库。
  • 共纳入69,332例年龄≥20岁的糖尿病合并外周动脉疾病患者。
  • 患者分为三组:他汀使用者11,409例,非他汀降脂药使用者4,430例,未使用者53,493例。

主要发现

  • 他汀使用者较未使用者下肢截肢校正风险比0.75(95%CI 0.62至0.90)。
  • 他汀使用者较未使用者院内心血管死亡校正风险比0.78(95%CI 0.69至0.87)。
  • 他汀使用者较未使用者全因死亡校正风险比0.73(95%CI 0.69至0.77)。
  • 倾向评分匹配分析中,他汀对下肢截肢风险的影响结果一致。
  • 考虑死亡竞争风险时,仅他汀使用者与下肢截肢风险降低相关(风险比0.77,95%CI 0.61至0.97)及心血管死亡风险降低相关(风险比0.78,95%CI 0.68至0.89)。

关键数值与推荐

  • 主要结局为下肢截肢,次要结局为院内心血管死亡和全因死亡。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Although there is evidence to support the beneficial effects of statins on major cardiovascular events, few studies address the protective effect of statins on limb outcome. OBJECTIVE: To investigate whether the use of statin is associated with a risk reduction in lower-extremity amputation in type 2 diabetes mellitus (DM) patients with peripheral arterial disease (PAD). DESIGN: Observational cohort study. SETTING: A nationwide DM database in Taiwan from 2000 to 2011. PATIENTS: A total of 69,332 patients aged ≥20 years with DM and PAD were identified. INTERVENTION: Patients were divided into three groups: 11,409 patients were statin users, 4430 patients used nonstatin lipid-lowering agents, and 53,493 patients were nonusers. MAIN OUTCOME MEASURES: The primary outcome was lower-extremity amputation. Secondary outcomes were in-hospital cardiovascular death and all-cause mortality. RESULTS: Compared with nonusers, statin users were associated with lower risks of lower-extremity amputation [adjusted hazard ration (aHR), 0.75; 95% confidence interval (CI), 0.62 to 0.90], in-hospital cardiovascular death (aHR, 0.78; 95% CI, 0.69 to 0.87), and all-cause mortality (aHR, 0.73; 95% CI, 0.69 to 0.77). In the propensity score matching analysis, the effect of statin on the risk of lower-extremity amputation was consistent. Only statin users were associated with the risk reduction of lower-extremities amputation (HR, 0.77; 95% CI, 0.61 to 0.97) and cardiovascular death (HR, 0.78; 95% CI, 0.68 to 0.89) when taking competing risk of death into consideration. CONCLUSIONS: Compared with statin nonusers who were never treated with lipid-lowering drugs, this study found that statin users had a lower risk of lower-extremity amputation and cardiovascular death in patients with DM and PAD.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Hsu CY, Chen YT, Su YW, et al. Statin Therapy Reduces Future Risk of Lower-Limb Amputation in Patients With Diabetes and Peripheral Artery Disease. J Clin Endocrinol Metab. 2017. PMID: 28398564. doi:10.1210/jc.2016-3717

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。